The present study aimed to prepare nanofibers by electrospinning in the system polylactic acid-hydroxyapatite-doxycycline (PLA-HAP-Doxy) to be used as a drug delivery vehicle. Two different routes were employed for the preparation of Doxy-containing nanofibers: Immobilization on the electrospun mat's surface and encapsulation in the fiber structure. The nanofibers obtained by Doxy encapsulation were characterized using Fourier transform infrared (FTIR) spectroscopy, thermogravimetric (TG) and differential thermal analyses (DTA) and scanning electron microscopy (SEM). The adsorption properties of pure PLA and PLA-HAP nanofibers were investigated for solutions with different Doxy concentrations (3, 7 and 12 wt%). Moreover, the desorption properties of the active substance were tested in two different fluids, simulated body fluid (SBF) and phosphate buffer solution (PBS), to evidence the drug release properties. In vitro drug release studies were performed and different drug release kinetics were assessed to confirm the use of these nanofiber materials as efficient drug delivery vehicles. The obtained results indicate that the PLA-HAP-Doxy is a promising system for biomedical applications, the samples with 3 and 7 wt% of Doxy-loaded PLA-HAP nanofibers prepared by physical adsorption are the most acceptable membranes to provide prolonged release in PBS/SBF rather than an immediate release of Doxy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951507 | PMC |
http://dx.doi.org/10.3390/ma15062105 | DOI Listing |
Front Biosci (Elite Ed)
October 2024
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, 1983969411 Tehran, Iran.
Background: Regenerative endodontics requires an innovative delivery system to release antibiotics/growth factors in a sequential trend. This study focuses on developing/characterizing a thermoresponsive core-shell hydrogel designed for targeted drug delivery in endodontics.
Methods: The core-shell chitosan-alginate microparticles were prepared by electrospraying to deliver bone morphogenic protein-2 for 14 days and transforming growth factor-beta 1 (TGF-β1) for 7-14 days.
Biomater Res
December 2024
Department of Neurosurgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China.
Glioblastoma multiforme (GBM) is among the most challenging malignant brain tumors, making the development of new treatment strategies highly necessary. Glioma stem cells (GSCs) markedly contribute to drug resistance, radiation resistance, and tumor recurrence in GBM. The therapeutic potential of nanomaterials targeting GSCs in GBM urgently needs to be explored.
View Article and Find Full Text PDFOncol Res
December 2024
Department of Biology, College of Science, Sultan Qaboos University, Muscat, 123, Oman.
Nanotechnology in cancer therapy has significantly advanced treatment precision, effectiveness, and safety, improving patient outcomes and personalized care. Engineered smart nanoparticles and cell-based therapies are designed to target tumor cells, precisely sensing the tumor microenvironment (TME) and sparing normal cells. These nanoparticles enhance drug accumulation in tumors by solubilizing insoluble compounds or preventing their degradation, and they can also overcome therapy resistance and deliver multiple drugs simultaneously.
View Article and Find Full Text PDFOncol Res
December 2024
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI), Dublin, D02 YN77, Ireland.
Brain metastasis and primary glioblastoma multiforme represent the most common and lethal malignant brain tumors. Its median survival time is typically less than a year after diagnosis. One of the major challenges in treating these cancers is the efficiency of the transport of drugs to the central nervous system.
View Article and Find Full Text PDF3 Biotech
January 2025
Department of Biotechnology, University of Calicut, Kerala Malappuram, 673635 India.
Rapamycin analogs are approved by the FDA for breast and renal cancer treatment. Hence, the possibility of nanoparticle-mediated delivery of Rapamycin could be examined. In the present study, PEGylated Gold-core shell iron oxide nanoparticles were used for the targeted delivery of Rapamycin, and R-Au-IONPs were formulated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!